|
Objective: To investigate thymosin α1 sepsis (sepsis) in patients with peripheral T-cell subsets, immunoglobulin IgG, IgA, IgM, complement C3, C4, C-reactive protein (C-reactive protein, CRP), procalcitonin (procalcitonin, PCT), interleukin -6 (interleukin-6, IL-6), interleukin -10 (interleukin-10, IL-10) the impact of thymosin α1 also observed in patients with sepsis and acute physiology chronic health evaluation Ⅱ (acute physiology and chronic heath evaluation, APACHE Ⅱ), the intensive care unit (ICU) time and 28 day mortality, evaluation of thymosin α1 on immune function of patients with sepsis and efficacy. Methods: The study was a randomized, controlled clinical study. Select ICU patients with sepsis 42 cases, all patients were consistent with 2001 Washington \treatment of sepsis treatment guidelines, thymosin α1 therapy group in the conventional treatment group based on the use of thymosin α11.6mg subcutaneously once / day for 7 days. Respectively before treatment (Do) and three days after treatment (D3), 7 天 (D7) specimens were checked T cell subsets, immunoglobulin IgG, IgA, IgM, complement C3, C4, C-reactive protein, calcitonin plasminogen, liver, kidney function, blood, peripheral blood specimens from another 2m1, be centrifuged and the serum stored at -70 ℃, measured by ELISA IL-6, IL-10 concentration; and record APACHE Ⅱ score, ICU stay time and 28 day mortality. Results: Thymosin α1 treatment group than in the treatment group compared before 7 days after treatment CD4 T cells, CD4 / CD8 were increased, the difference was statistically significant (P lt; 0.05); thymosin α1 therapy group than in the conventional treatment group CD4 T cells , CD4 / CD8 ratio after treatment, 3 days, 7 days increased significantly, and the difference was statistically significant (P lt; 0.05). Thymosin α1 treatment group than in the conventional treatment group, immunoglobulins IgG, complement C3, inflammatory cytokine IL-10 were increased in the course of treatment, the difference was statistically significant (P lt; 0.05). Thymosin α1 treatment group than in the conventional treatment group seven days after treatment, C-reactive protein, PCT, IL-6 were significantly decreased, the difference was statistically significant (P lt; 0.05). Thymosin α1 treatment group and the conventional treatment group before treatment all parameters showed no significant difference (P gt; 0.05), thymosin α1 therapy group than in the conventional treatment group after treatment, APACHE II score was significantly decreased, the difference was statistically significant (P lt; 0.05). Thymosin α1 treatment group than in the conventional treatment group shortened ICU stay, the difference was statistically significant (P lt; 0.05), thymosin α1 therapy group than in the conventional treatment group, 28 day mortality decreased, the difference was not statistically significant (P gt; 0.05). Conclusion: Thymosin α1 treatment of sepsis patients can enhance their cellular immunity, humoral immunity, improve the inflammatory response, improve the condition and reduce the duration of ICU stay, is not yet clear whether the improvement in the prognosis of patients with sepsis.
|